Philip M. Leonard

Charles River, Chesterford Research Park
Saffron Walden, ENG CB101XL, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.

Journal: Journal of medicinal chemistry

Published: March 30, 2021

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.

Journal: Journal of medicinal chemistry

Published: March 15, 2021

[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.

[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.

Journal: Journal of medicinal chemistry

Published: October 27, 2020

Bending the Curve of Global Freshwater Biodiversity Loss: An Emergency Recovery Plan.

Bending the Curve of Global Freshwater Biodiversity Loss: An Emergency Recovery Plan.

Journal: Bioscience

Published: April 15, 2020

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Journal: Journal of medicinal chemistry

Published: March 07, 2019

Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).

Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).

Journal: Journal of medicinal chemistry

Published: August 09, 2016

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 30, 2015

Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.

Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.

Journal: Journal of medicinal chemistry

Published: March 12, 2015

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Journal: Journal of medicinal chemistry

Published: November 23, 2013

Will expansion of the NHS abroad benefit UK patients? Yes.

Will expansion of the NHS abroad benefit UK patients? Yes.

Journal: BMJ (Clinical research ed.)

Published: January 04, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026